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National drug strategy  
and coordination
National drug strategy
In Spain, the National Drug Strategy (2009-16) primarily 
focused on illicit drugs but also considered licit 
substances (Figure 1). Its objectives included reducing 
the use of licit and illicit substances; delaying the age 
at first contact with drugs; guaranteeing high-quality 
assistance adapted to the needs of all people affected 
by drug use; reducing or limiting the harm caused to 
drug users’ health; and facilitating the social integration 
of drug users. The strategy was built around five fields of 
action: (i) demand reduction (prevention, risk and harm 
reduction, treatment and social reintegration); (ii) supply 
reduction; (iii) improvement of basic and applied scientific 
knowledge; (iv) training; and (v) international cooperation. 
Two consecutive four-year action plans were drawn up 
to implement specific actions for the periods 2009-12 
and 2013-16. A new National Drug Strategy for the period 
2017-24 is being developed, and will cover mainly illicit 
drugs, but also licit substances, such as alcohol. 
Like other European countries, Spain evaluates its drug 
policy and strategy using ongoing indicator monitoring 
and specific research projects. A mixed methods final 
internal evaluation of the National Strategy on Drugs 
(2000-08) was completed in 2008 and examined the 
strategy’s implementation. In 2012, an internal evaluation 
of the 2009-12 action plan and, in 2014, a mid-term 
evaluation of the 2013-16 action plan were completed 
by the Government Delegation for the National Plan on 
Drugs. A final evaluation of the 2013-16 action plan and 
a final evaluation of the National Drug Strategy (2009-
16) will be completed in 2017 in the context of the 
development of the new strategy.
National coordination mechanisms
At the national level, the Spanish Council for Drug 
Addiction and Other Addictions is responsible for inter-
sectorial collaboration. It seeks to improve the development 
and implementation of policies and actions related to illicit 
drug and other addictions. The Government Delegation 
for the National Plan on Drugs is the national drug policy 
coordinator. The Delegate’s office is a directorate of 
the Ministry of Health, Social Services and Equality. It 
coordinates the institutions involved in delivering the drug 
strategy at central administrative, regional/autonomous 
community and local levels.
The Sectoral Conference on Drugs facilitates cooperation 
between central government and the administrations 
of the autonomous communities and cities. Chaired by 
the Minister for Health, Social Services and Equality, it is 
made up of representatives of the central administration 
and the regional ministers of the Departments of the 
Autonomous Regions. The Communities Commission 
on Drugs, chaired by the Government Delegate for the 
National Plan on Drugs, reports to the sector conference, 
which is made up of all the deputy directors-general of 
the government delegation and those responsible for the 
regional drug plans (commonly known as regional drug 
commissioners). There is a drug commissioner in each of 
the 17 autonomous communities and in two autonomous 
FIGURE 1
Focus of national drug strategy documents:  





NB: Year of data 2015. Strategies with broader focus may include,  
for example, licit drugs and other addictions.
About this report
This report presents the top-level overview of the drug 
phenomenon in Spain, covering drug supply, use and 
public health problems as well as drug policy and 
responses. The statistical data reported relate to 2015 (or 
most recent year) and are provided to the EMCDDA by the 
national focal point, unless stated otherwise.
An interactive version of this publication, containing links to 
online content, is available in PDF, EPUB and HTML format: 
www.emcdda.europa.eu/countries
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cities (Ceuta and Melilla). They communicate with the 
Government Delegation through their participation in the 
Inter-autonomic Commission and the sector conference.
 A new National Drug  
 Strategy for the period  
 2017-24 is being  
 developed and will cover  
 illicit drugs and licit  
 substances, such as alcohol  
Public expenditure
Understanding the costs of drug-related actions is an 
important aspect of drug policy. Some of the funds 
allocated by governments to expenditure on tasks related 
to drugs are identified as such in the budget (‘labelled’). 
Often, however, the majority of drug-related expenditure is 
not identified (‘unlabelled’) and must be estimated using 
modelling approaches.
In Spain, the National Drug Strategy and the action plans 
have associated budgets but actual expenditure is not 
reviewed. A 2002 study looked at the social costs of drug 
use and included an estimate of drug-related expenditure. 
The study did not, however, distinguish between public and 
private expenditure.
Spanish authorities provide partial estimates of drug-
related public expenditure by central government and 
by the autonomous communities and cities every year. 
However, the estimates do not cover all sectors and 
include labelled and unlabelled expenditure. Comparability 
over time is limited because reporting entities and data 
collection methods have changed.
In 2013 and 2014, drug-related public expenditure was 
estimated to represent 0.03 % of gross domestic product. 
Most of the total of approximately EUR 333 million (about 
65 %) was spent by the autonomous communities and 
cities, while the remaining 35 % was spent by the central 
government. In 2012, the autonomous communities 
spent more than four fifths of their expenditure on 
treatment, while the rest was spent on prevention, research 
and institutional cooperation. Estimates for the total 
expenditures of local governments are not available. The 
available information does not allow the total amount and 
trends in drug-related public expenditures to be reported.
 In 2014, drug-related  
 public expenditure  
 represented 0.03 % of  
 gross domestic product 
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Drug laws and drug law offences
National drug laws
In Spain, consumption or minor personal possession in public 
places is deemed a serious order offence, punishable by 
administrative sanctions (Figure 2), with fines of EUR 601 to 
EUR 30 000 [Law on the Protection of Citizens’ Security (2015), 
Article 36]. For minors, the fine can be suspended if the offender 
voluntarily attends treatment, rehabilitation or counselling 
activities. 
Drug trafficking offences and penalties are defined in the 
Criminal Code, Articles 368-378. Penalty ranges are determined 
by the seriousness of the health damage associated with 
the drugs involved and any aggravating and mitigating 
circumstances that may exist, such as selling to minors or 
the sale of large quantities. Prison sentences ranging from 
one to three years can be imposed if the drugs do not cause 
serious damage to health, and can be up to six years if they 
do. When aggravating circumstances exist, penalties can be 
up to 21 years in prison. In all cases, a fine is also imposed and 
substances, instruments of crime and profits are confiscated; 
disqualification from professions is also an option. Both legal 
entities and individuals may be punished. Under Article 376, 
prison sentences (of up to five years) may be reduced if an 
offender who was dependent on drugs at the time of the crime 
successfully completes detoxification treatment.
New psychoactive substances (NPS) are controlled by adding 
them to the lists of substances subject to the Citizens’ Security 
law and the Criminal Code, as above.
Drug law offences
Drug law offence (DLO) data are the foundation for 
monitoring drug-related crime and are also a measure of 
law enforcement activity and drug market dynamics; they 
may be used to inform policies on the implementation of 
drug laws and to improve strategies. 
In Spain, the overwhelming majority of drug law offenders 
are charged with possession-related offences against 
the Law on the Protection of Citizens’ Security, while the 
remainder are charged with penal offences (Figure 3).  
In 8 out of 10 cases, charges are associated with cannabis. 
FIGURE 2
Legal penalties: the possibility of incarceration for 
possession of drugs for personal use (minor offence)
Spain
Not for minor 
drug possession
For any minor 
drug possession
Not for minor cannabis 
possession, but 
possible for other 
drug possession
Not for minor 
drug possession
FIGURE 3





NB: Year of data 2015.
NB: Year of data 2015.




The prevalence of use of illicit substances in Spain 
has been relatively stable over the last few years, with 
approximately one third of the adult population reporting 
lifetime use of an illicit substance. Cannabis, followed by 
cocaine, is the most commonly used drug, with use mainly 
concentrated among adolescents and adults below 35 
years. Although the latest available data from the 2015 
general population study confirm that the prevalence of 
use of both substances has declined in the last 10 years, 
the levels of cannabis and cocaine use in Spain remain 
higher than in other European Union countries. 
The available data highlight that ‘experimentation’ with 
cannabis has become more ‘habitual’ among today’s 
younger Spanish generation; however, although persistent 
use remains low, those who continue to use cannabis do 
so almost daily. The use of all illicit substances remains 
more prevalent among males than females (Figure 4).
The prevalence of the use of NPS has remained stable 
since 2011, with about 3.4 % of adults in the 2015 study 
reporting ever having used NPS. Most NPS users are young 
males who exhibit patterns of experimental polydrug use. In 
general, polydrug use remains a very common consumption 
pattern, especially among those aged 18 and over.
Four Spanish cities (Barcelona, Castellón, Molina de 
Segura and Valencia) participate in the Europe-wide 
annual wastewater campaigns undertaken by the Sewage 
Analysis Core Group Europe (SCORE). This study provides 
data on drug use at a community level, based on the levels 
of illicit drugs and their metabolites in wastewater sources. 
The results of the 2016 study on stimulant drugs revealed 
high levels of cocaine metabolites in wastewater samples 
from all cities studied, and higher than levels reported 
from some other European cities participating in the study. 
In addition, Barcelona recorded an increase in MDMA/
ecstasy residues between 2011 and 2016. A common 
pattern across the monitored cities was an increased use 
of cocaine and MDMA at weekends.
FIGURE 4
Estimates of last-year drug use among young adults (15-34 years) in Spain
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NB: Estimated last-year prevalence of drug use in 2015.
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Data on drug use among 14- to 18-year-old students 
come from The programme of State Surveys on Drug 
Use in Secondary Schools (ESTUDES), which has been 
conducted every second year in Spain since 1994. The 
2014 study confirmed that the most commonly used illicit 
substance is cannabis, with about 3 out of 10 students 
admitting to having used it in the past. However, there was a 
slight increase in the proportion of students who had used 
cannabis in preceding 30 days (18.6 % in 2014; 16.1 % 
in 2012). Lifetime prevalence rates for other illicit drugs 
among the students remain well below that for cannabis. 
ESTUDES also supplies data to the European School Project 
on Alcohol and Drugs (ESPAD), and the 2014 data indicated 
that prevalence of lifetime cannabis use among Spanish 
students aged 15-16 years was higher than the ESPAD 
average (35 countries) (Figure 5).
High-risk drug use and trends 
Studies reporting estimates of high-risk drug use can help 
to identify the extent of the more entrenched drug use 
problems, while data on first-time entrants to specialised 
drug treatment centres, when considered alongside other 
indicators, can inform understanding on the nature and 
trends in high-risk drug use (Figure 7).
In Spain, heroin remains the main substance linked to 
serious adverse health and social consequences, such as 
drug-related infections. The estimated number of high-risk 
heroin users has shown a decreasing trend since 2010, 
and remained stable in 2013-14 (Figure 6). The number of 
high-risk cocaine users in Spain has been falling since 2009. 
Injecting drug use has also declined in the last 30 years 
among those admitted to treatment. 
 Heroin remains the main  
 substance linked to serious   
 adverse consequences but  
 the estimated number of  
 high-risk heroin users has  
 remained relatively stable 
FIGURE 5
Substance use among 15- to 16- year-old school students in Spain
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Source: ESTUDES (2014) and ESPAD study 2015.
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Data from specialised treatment centres indicate that 
cocaine remains the substance resulting in the highest 
number of treatment entries, while the number of first-time 
clients reporting cocaine as the primary substance of use 
has decreased. Moreover, only a small proportion of cocaine 
users entering treatment reported injecting drug use.
Additional data from treatment centres indicate that 
cannabis has progressively become the main primary 
substance among those who enter the treatment for the 
first time (Figure 7). This corresponds to the findings of the 
last general population study, while the 2014 ESTUDES 
indicated a slight decline in daily cannabis users.
FIGURE 7
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NB: Year of data 2015, or latest available year.
NB: Year of data 2014. Data is for first-time entrants, except for gender which is for all treatment entrants.




In the last 20 years, human immunodeficiency virus (HIV) 
infection has represented one of the main health problems 
associated with drug use in Spain. However, since the end 
of the 1990s, a significant decrease has been observed in 
HIV infection associated with injecting drug use (Figure 8). 
Although the incidence of HIV infection remains low, in 
2014, approximately one third of people who have ever 
injected drugs and entered treatment in Spain were 
HIV positive. Information on hepatitis C virus (HCV) and 
hepatitis B virus (HBV) infection among people who inject 
drugs (PWID) at the national level is routinely collected 
through the treatment demand indicator, with the first 
data on self-reported HBV and HCV status available from 
2014 (Figure 9). A recently published cohort study reported 
that up to three quarters of PWID are HCV positive (as 
determined by the presence of anti-HCV antibodies).
Drug-related emergencies
Information on drug-related emergencies in Spain 
originates from the National Plan on Drugs, which 
was introduced in 1987, and which monitors hospital 
emergencies directly caused by non-medical use of 
psychoactive substances among 15- to 54-year-olds. In 
2014, 6 441 emergency episodes related to drug use 
were notified, continuing the rather stable trend seen 
over the previous five years. Cocaine was the substance 
most frequently reported as the cause of the emergency 
episodes, followed by cannabis. The proportion of 
cannabis-related emergency episodes shows a clear 
upward trend since 2000, while the proportion of 
heroin-related intoxications fell by a factor of 3 during 
the same period. Amphetamines and MDMA were less 
common causes of drug-related emergencies in Spain in 
2014; however, there are some indications of an upward 
trend in the last five years.
FIGURE 9 
Prevalence of HIV and HCV antibodies among people who 
inject drugs in Spain 
HIV antibody 
prevalence among 















people who inject drugs
NB: Year of data 2014.
FIGURE 8 











NB: Year of data 2015, or latest available year. 
Source: ECDC.
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Drug-induced deaths and mortality
Drug-induced deaths are deaths that can be attributed 
directly to the use of illicit drugs (i.e. poisonings and 
overdoses). 
The Special Registry, based on forensic and toxicological 
sources, indicated stable trends in drug-induced deaths in 
the last five years, with 556 drug-induced deaths reported 
in 2014. According to the available toxicological results, 
opioids, followed by cocaine, were found in the majority 
of deaths; however, there has been a decrease in the 
proportion of deaths attributed to both substances in 
recent years. Most victims were male and more than half 
were older than 45 years, which mirrors the ageing of the 
Spanish heroin users’ cohort.
In 2014, the General Mortality Register (GMR) reported 455 
drug-induced deaths according to the national definition 
(Figure 10).
Data from a recent mortality study in Spain suggest that 
4 out of 100 overdoses among 18- to 30-year-old heroin 
users are fatal. Another study examined mortality among 
a cohort of cocaine users admitted for treatment in Spain. 
The results indicate that the age-standardised mortality 
among those who use cocaine and heroin, or only cocaine, 
is higher than that of the general population.
The drug-induced mortality rate among adults (aged 15-64 
years) is 14.8 deaths per million in 2014 (Figure 11), which 
is lower than the latest estimated European average of 
20.3 deaths per million. 
 
FIGURE 10 
Characteristics of and trends in drug-induced deaths in Spain
Gender distribution Age distribution of deaths in 2014
Trends in the number of drug-induced deaths































Cases per million population
Spain
14.8
NB: Year of data 2014.  
Source: the General Mortality Register.
NB: Year of data 2015, or latest available year.
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Prevention
In Spain, drug prevention is a priority in the National Strategy 
on Drugs 2009-16 and the latest action plan, which provided 
an organisational and financial framework at the national 
level and at the level of autonomous communities through 
Autonomic Drug Plans and Municipal Drug Plans. Community-
based programmes may also receive funding from the fund 
of assets seized from illegal drug trafficking and other related 
offences, and, very occasionally, from foundations. The main 
features of the prevention policy are a focus on both licit and 
illicit substances, strong cooperation with the educational 
system and the recent increase in interventions in selective and 
indicated prevention. Non-governmental organisations, funded 
through public calls or tenders, are key to the implementation of 
prevention activities at the grassroots level.
Prevention interventions
Prevention interventions encompass a wide range of 
approaches, which are complementary. Environmental 
and universal strategies target entire populations, selective 
prevention targets vulnerable groups that may be at 
greater risk of developing drug use problems and indicated 
prevention focuses on at-risk individuals. 
In Spain, the introduction of environmental prevention 
measures, such as limiting access to alcohol, is the 
responsibility of autonomous communities. 
Universal prevention in Spain is mainly implemented in the 
educational sector, and it is focused on the development 
of personal and family competences and skills. Reports 
from the autonomous communities indicate a decrease 
in school-based programmes in recent years, while the 
number of family-based interventions has increased. In 
the educational environment, a wide variety of manual-
based prevention programmes in classrooms are used, and 
extracurricular activities and training are available. Few of 
these have been evaluated so far (Figure 12). 
Community-based prevention programmes organised 
by health centres are becoming increasingly available 
in schools and mainly focus on information provision 
through a range of support materials. Schools provide 
educational talks for parents, distribute materials and 
offer orientation and guidance services and informal 
courses. Increasing numbers of on-line ‘parents’ schools’, 
which inform parents about drugs and give advice about 
parenting skills, are available. An initiative for family-based 
prevention, Prevención Familiar, has been set up as a 
mutual empowerment initiative with parents’ associations, 
providing materials for professionals and families.
Prevention programmes in universities have emerged in recent 
years and focus mainly on information provision and awareness 
raising, using peer education methods or online delivery.
Universal community-based prevention programmes are 
largely provided through alternative leisure programmes in 
youth clubs, sports centres, schools and community centres, 
and activities are recreational and sports related. Programmes 
conducted in places where drug use is common, such as 
bars, nightclubs and music concerts, are carried out by 
peer mediators, who work to identify problematic cases and 
provide information and advice about drugs and their various 
forms of use. Environmental approaches in this setting 
are rare. Only a few autonomous communities implement 
programmes, such as Platform for Quality Leisure in the 
Balearic Islands, Q for Quality in Catalonia and Responsible 
Serving of Alcoholic Beverages in Castilla and Leon.
Selective prevention activities focus on young people in 
disadvantaged neighbourhoods and those in specific 
educational or residential centres. Selective prevention 
programmes for families at risk, female former drug users 
with children and specific programmes for ethnic minorities 
and for young people with drug use problems and families 
affected by drug use are available.
Indicated prevention activities in Spain are frequently 
associated with selective prevention activities and address 
both vulnerable young people and families, aiming to alleviate 
risk and promote protective factors at an individual level. For 
example, Empecemos (Let’s Begin) is a well-researched 
indicated prevention programme with promising long-
term outcomes for disruptive children in Galicia. Several 
autonomous communities have reported prevention activities 
focusing on under-age offenders with drug use problems.
FIGURE 12 
Provision of interventions in schools in Spain  
(expert ratings) 
5 - Full provision
4 - Extensive provision
3 - Limited provision
2 - Rare provision
1 - No provision
0 - No information available
Spain
EU Average
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NB: Year of data 2016.
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Harm reduction
The reduction of drug-related risk and harm is one of the 
principal objectives of the National Drug Strategy for 2009-
16, and further detailed in four-year action plans for 2009-
12 and 2013-16. There is a particular focus on activities 
that facilitate contacts with PWID, provide information and 
education, and promote behaviour and practice change. 
National priorities for the prevention of infectious diseases 
among drug users include support for needle and syringe 
programmes (NSPs), voluntary counselling and testing for 
infections, and hepatitis vaccination programmes.
Harm reduction interventions
Harm reduction services are provided by a large public 
network of facilities, including social emergency centres, 
mobile units, pharmacies and prisons.
Most harm reduction programmes include a socio-sanitary 
service that offers preventive educational interventions, 
overdose prevention activities, sterile needles and syringes, 
testing for drug-related infections, vaccination against 
hepatitis A virus and HBV and emergency care and 
assistance to injecting drug users, who are not usually in 
contact with any assistance intervention (Figure 13). 
In 2014, public NSPs in Spain distributed approximately 
1.5 million syringes, continuing a declining trend that 
started in 2005. This trend coincided with the scaling 
up of opioid substitution treatment (OST), which has 
been shown by the available evidence to have a positive 
outcome for treatment retention and reduction in illicit 
opioid use, reported risk behaviour and drug-related 
harms and mortality. The drop in the number of syringes 
distributed is also thought to be the result of a reduction 
in the prevalence of injecting drug use in Spain. Thirteen 
FIGURE 13 





































NB: Year of data 2016.
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facilities for supervised drug consumption are available in 
the autonomous communities of Catalonia and the Basque 
Country. In 2014, these facilities served 5 900 clients.
 In 2014, public needle  
 and syringe programmes  
 in Spain distributed  
 approximately 1.5 million  
 syringes, continuing a  
 declining trend that  
 started in 2005 
Treatment
The treatment system
In Spain, the overall policy for drug treatment is guided 
by the National Drug Strategy. At the same time, the 
implementation, management and evaluation of the 
resources and programmes for providing care for drug 
users come under the authority of the 17 autonomous 
communities and the two cities. Each autonomous 
community is entitled to organise and deliver health 
interventions according to its own plans, budgets and 
personnel. Some have integrated treatment for drug use-
related problems within primary care units or mental health 
services, and some have a separate treatment network that 
retains a connection with the general healthcare system. 
As a general rule, care is organised on three levels. The level 
of primary care acts as a gatekeeper, the secondary level 
provides integrated treatment services, and tertiary-level 
care units supply highly specialised and long-term care.
The public sector is the primary provider of treatment, 
followed by non-government organisations (NGOs) and 
private organisations. Drug treatment is mostly funded by 
the public budget of the central government, autonomous 
communities and cities and by some municipalities, usually 
the big cities. 
A specific drug dependence care network is widely 
distributed throughout the country. Therapeutic provision 
comprises outpatient and inpatient treatment networks.
The outpatient network includes low-threshold services, 
mainly operating at the first care level and providing mental 
health screening for clients, and specialised drug treatment 
centres, including mental health units, which constitute 
the backbone of the treatment system, operating at the 
secondary level. A team of multidisciplinary staff usually 
manages clients in those settings, providing psychosocial 
treatment, case management and referral to other services.
The inpatient networks include hospital detoxification units, 
support apartments for treatment and social reintegration, 
therapeutic communities and penitentiary centres.
In Spain, OST is available at about 2 000 specialised 
outpatient centres, at other health and mental health 
centres, at inpatient facilities and in prisons. Pharmacies 
are involved in dispensing medication to patients. 
Methadone was introduced and licensed as a treatment in 
1990, and the treatment is free for clients. Buprenorphine-
based medication is offered by the National Health Service, 
but clients have to contribute to the cost of the medication.
FIGURE 14 
Drug treatment in Spain: settings and number treated 
Outpatient
Prison (774)
Prison (16 168) erapeutic
communities (10 814)
Low-threshold agencies (34 049)
Specialised treatment centres (114 837)
Inpatient
Hospital-based residential drug treatment (3 053)
Residential drug treatment (615)
Other oupatient setting (259)
NB: Year of data 2014.
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Treatment provision
In Spain, nearly 180 000 drug users received drug 
treatment in 2014, the majority of whom were treated 
in outpatient settings (Figure 14). Over the last decade, 
the number of clients entering treatment each year has 
ranged between 49 000 and 53 000. Heroin users remain 
the largest population receiving drug treatment in Spain, 
many of whom are long-term recipients of OST. However, 
data on the number of people entering drug treatment 
show that cocaine remains the most common primary 
drug among treatment clients entering care, followed 
by cannabis and opioids. Nevertheless, the proportion 
of people entering treatment as a result of heroin or 
cocaine use has declined over the last 10 years, while 
a progressive increase in cannabis-related demands 
has been observed; since 2012, the total number of 
treatment entries due to cannabis use has exceeded 
those due to heroin (Figure 15). This is mainly attributed 
to the progressive increase in new treatment entries due 
to primary cannabis use, as approximately 7 out of 10 
clients entering treatment due to primary cannabis use 
are first-time treatment entrants (Figure 7).
Methadone maintenance treatment remains the most 
frequent form of OST, while combined buprenorphine/
naloxone is mainly used at low doses for clients who were 
stabilised on methadone. Since 2002, a declining trend 
in the number of clients receiving OST in Spain has been 
reported, which is consistent with other data indicating an 
overall decline in the number of heroin users in the last two 
decades (Figure 16).
 The proportion of people  
 entering treatment as a  
 result of heroin or cocaine  
 use has declined over  
 the last 10 years, while a  
 progressive and significant  
 increase in cannabis-  
 related demands has been  
 observed 
FIGURE 15 
Trends in percentage of clients entering specialised drug 
treatment, by primary drug, in Spain
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Drug use and responses in prison
The General Secretariat of Penitentiary Institutions of the 
Ministry of Interior is responsible for prison administration 
in Spain, except in Catalonia. Healthcare provision in 
prisons is the responsibility of the Ministry of Interior, 
although in Catalonia and the Basque Country it is 
provided by the health services of these autonomous 
communities.
Drug treatment programmes in prisons are provided 
in partnership with various prison services (health, 
psychology, safety, etc.), and in close cooperation with 
available services outside prisons, such as drug treatment 
facilities, social services and NGOs. Three organisational 
structures in each prison are involved in the provision of 
these services: the commission on drug dependence, the 
sanitary team and the drug dependence team.
A 2011 survey on drug use among inmates in Spain 
reported that cannabis was the most common drug used 
in the 30 days prior to imprisonment (40 %), followed by 
cocaine (27 %), while heroin use was reported by 14 % of 
inmates. Injecting drug use was reported by 5 % in the 30 
days prior to imprisonment, which was a decrease from 
2006 (11 %). Cannabis was the drug most commonly used 
in prison (21 %), while use of other drugs was much lower 
and injecting drug use was reported by only 0.4 %. Polydrug 
use was common among drug users in prison. One third of 
those who inject drugs in prison are HIV positive and three 
quarters are HCV positive.
Health programmes implemented in prisons (treatment of 
HIV, HCV and tuberculosis, vaccinations and mental health) 
and drug-related intervention programmes — prevention, 
health education, health mediators (recruited among 
inmates), harm and risk reduction (syringe exchange, 
distribution of aluminium foil and condoms, overdose 
action programme) and treatment of the dependency 
(opioid substitution, detoxification) — have all contributed 
to reductions in morbidity and mortality among inmates in 
penitentiary institutions. 
Methadone maintenance treatment constitutes one of the 
most effective intervention programmes in terms of risk 
reduction related to opioid use. It is an important part of 
drug treatment in Spanish prisons, and many drug users 
benefit from it. 
The first needle and syringe exchange programme in a 
Spanish prison was introduced in Bilbao in 1997, and 
such programmes are now available in 47 prisons in 
Spain. The Bilbao programme received the First European 
Prize for Good Health Practices in Prisons awarded by the 
European Prison and Health Network of the World Health 
Organization (WHO).
Special social reintegration programmes offered in prisons 
provide drug users with the necessary skills to maintain 
treatment following release and support their reintegration 
into society.
 In 2011, cannabis was the  
 drug most commonly used  
 in prison (21 %), while use  
 of other drugs was much  
 lower and injecting drug  
 use was reported by only  
 0.4 % 
Quality assurance
The Spanish National Strategy on Drugs 2009-16 and the 
action plan for 2013-16 include quality as one of their 
basic principles and determine objectives related to the 
promotion of quality. The action plan includes actions 
directly related to quality. Action 30 focuses on the creation 
of a portal on Good Practices; and action 31 on criteria for 
accrediting demand reduction programmes. The remaining 
actions have the cross-cutting objective of developing of 
quality criteria in each field of work. 
Within the scope of action 30, support was provided for the 
creation of a portal for prevention programmes based on 
evidence produced by the organisation Socidrogalcohol. 
Another good practice portal focusing on reducing demand 
is under development.  
Within the scope of action 31 of the action plan, 
some minimum quality criteria for demand reduction 
programmes were approved. In addition, the Government 
Delegation for the National Plan on Drugs was an associate 
partner in The European Drug Prevention Quality Standards 
project. Various NGOs have also initiated processes for 
promoting good practices for management and work 
projects, supported by the Government Delegation.
The accreditation of demand reduction programmes 
in Spain is linked to their funding. Demand reduction 
programmes and services are funded mainly by the public 
administration and, to receive public money, they must be 
accredited (in the case of treatment) or pass through a 
series of more or less demanding quality filters according 
to the geographical area in which they are applied.
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In addition, in the National Strategy, training is both a cross-
cutting theme and a separate heading with associated 
objectives and actions. One of the aims of the current action 
plan is to produce a national training plan on drug problems.
 Demand reduction  
 programmes and services  
 are funded mainly the  
 public administration and,  
 to receive public money,  
 they must be accredited  
 (in the case of treatment)  
 or pass through a series  
 of more or less demanding  
 quality filters 
Drug-related research
In Spain, biomedical research and health sciences 
are important aspects of the national research and 
development agenda, which comes under the framework 
of the Spanish Strategy for Science, Technology and 
Innovation 2013-20 and the National Plan for Scientific and 
Technical Research and Innovation 2013-16. In addition to 
those documents, the National Strategy on Drugs 2009-16 
calls for improved research in areas of drug use, prevention 
and treatment, as well as for evaluation of programmes 
and actions. The research is funded through the general 
state budget through public tenders or calls.
The Government Delegation for the National Plan on Drugs is 
the national entity responsible for directing and coordinating 
drug-related research activities. Priority areas for drug-related 
research include basic, clinical, social, epidemiological and 
methodological research. The Action Plan on Drugs 2013-
16 promoted (i) surveys of the general population and 
young high school students; (ii) the compilation of data on 
treatment, emergencies and mortality; (iii) the strengthening 
of surveillance systems with new tools and epidemiological 
indicators on the use of drugs, such as the problematic 
drug use indicator or the drug-related infectious diseases 
indicator; (iv) research and analysis of data on drug use and 
gender, drug use in the workplace, polydrug use, etc.; (v) the 
dissemination of data from the Information System through 
publications and online media; (vi) the consolidation of the 
Early Warning System for the detection of NPS; (vii) research 
networks with a clinical and preventative focus, integrating the 
existing drug-related networks and research centres in Spain; 
and (viii) setting up a portal on best practices.
Recent drug-related studies funded by the Government 
Delegation focused mainly on basic and clinical research 
on alcohol, cocaine and cannabis. Priority research lines 
for the 2016 call for applications included selective and 
indicated prevention in associated or independent alcohol 
and cannabis abuse, especially in minors; the social cost 
of drug problems; improving the quality and results of 
the therapeutic process; strategies for social and labour 
reintegration; actions in prison settings; and prevention and 
intervention in drug dependency in the workplace.
University departments and research networks are the main 
actors undertaking drug-related research. National scientific 
journals and specialised websites are the main channels for 
national dissemination of drug-related research findings. 
Recently, the EU-funded Ibero-American Library on Drugs 
and Drug Addiction (BIDA, in Spanish) was established, and 
international cooperation in drug research is in place (i.e. with 
the US National Institute on Drug Abuse).
 Recent drug-related  
 studies funded by the  
 Government Delegation  
 focused mainly on basic  
 and clinical research  
 on alcohol,  
 cocaine and cannabis 
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Drug markets 
Owing to its geographical position, Spain is one of the 
countries in the European Union that is most targeted by 
international drug traffickers, especially for the transit of 
cannabis resin and cocaine to other European countries. 
Therefore, actions to discover and dismantle international 
criminal networks involved in the trafficking of drugs are 
priorities of the Spanish law enforcement agencies and 
are carried out through intensifying control in the southern 
coastal areas and ports for packages of drugs; investigating, 
discovering and confiscating the proceeds of drug trafficking 
and money laundering; preventing the distribution of 
illegal drugs within the country; and fostering international 
cooperation. In this context, Spain remains one of the 
European countries reporting large seizures of cocaine and 
cannabis resin, in terms of both number of seizures and 
quantities seized. According to information from drug law 
enforcement agencies, seized cocaine generally originates 
from Colombia, Bolivia and Peru and arrives in Spain directly 
or via Central or South American countries by sea.
Nearly all cannabis resin seized by the Spanish law 
enforcement bodies comes directly from Morocco; 
however, in recent years, the eastern Mediterranean route 
has emerged for the trafficking of cannabis products, 
mainly from Morocco. Cannabis is also cultivated in Spain; 
there are indications that its production has increased 
since 2009, and is intended to supply local demand as well 
as being trafficked to other European Union countries.
Heroin comes mainly from Pakistan via the Balkan route, 
and arrives in Spain mainly by air.
Historically, synthetic drugs were mainly smuggled into 
Spain from the Netherlands and Belgium, while in the 
recent years there have been seizures of MDMA that 
was produced in France or Andorra; in 2014, there was 
a significant seizure (of approximately 400 000 units) of 
MDMA originating in Bulgaria.
Overall, the number of drug seizures has increased over 
the past decade, and cannabis products remain the illicit 
drugs most frequently seized in Spain. An overall decline 
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in cannabis resin seizures has been noted since 2009; 
however, the quantity of resin seized has increased since 
2010. In 2015, an increase in the quantity of herbal cannabis 
from large-scale seizures was reported, while the amounts 
seized in small-scale seizures were lower than in 2014.
Cocaine remains the second most frequently seized illicit 
drug, although, since 2009, a declining trend in cocaine 
seizures has been reported. In 2013-15, an increase in the 
number of heroin seizures, mainly small scale, was noted. 
The amount of heroin seized also increased over the same 
period, but this increase was mainly due to large-scale 
seizures. Spain reported a reduction in large-scale seizures 
of synthetic stimulants (amphetamines and MDMA) in 2015 
compared with 2014. Small-scale seizures of MDMA in 2015 
were lower than in 2014, while seizures of amphetamines 
have gradually increased since 2013 (Figure 17).
Spain reports mean potency (% of THC) or purity (% or mg 
per tablet) and average prices for the main illicit drugs. The 
mean potency for cannabis resin in 2013 was 14.5 % of 
THC, while for herbal cannabis it was 10.8 % of THC. The 
mean purity for heroin in 2015 was reported at 33 % and 
cocaine 42 %. In 2015, the mean price of cannabis resin 
was around 6 Euro/g, herbal cannabis 5 Euro/g, heroin 
58 Euro/g, cocaine – 59 Euro/g, amphetamine 28 Euro/g. 
The mean price for one MDMA dose was 11 Euro.
 Spain is the country  
 reporting the largest  
 seizures of cocaine and  
 cannabis among the EU  
 member States 
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KEY DRUG STATISTICS FOR SPAIN
Most recent estimates and data reported
   EU range
 Year Country data Minimum Maximum
Cannabis     
Lifetime prevalence of use — schools  
(% , Source: ESTUDES (2014) and ESPAD)
2015 26.6 6.5 36.8
Last year prevalence of use — young adults (%) 2015 17.1 0.4 22.1
Last year prevalence of drug use — all adults (%) 2015 9.5 0.3 11.1
All treatment entrants (%) 2014 34 3 71
First-time treatment entrants (%) 2014 48 8 79
Quantity of herbal cannabis seized (kg) 2015 15 915.4 4 45 816
Number of herbal cannabis seizures 2015 156 984  106 156 984
Quantity of cannabis resin seized (kg) 2015 380 360.9 1 380 361
Number of cannabis resin seizures 2015 164 760  14 164 760
Potency — herbal (% THC)  
(minimum and maximum values registered)
No data No data 0 46
Potency — resin (% THC)  
(minimum and maximum values registered)
No data No data 0 87.4
Price per gram — herbal (EUR) 
(minimum and maximum values registered)
No data No data 0.6 31.1
Price per gram — resin (EUR)  
(minimum and maximum values registered)
No data No data 0.9 46.6
Cocaine     
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 2.1 0.9 4.9
Last year prevalence of use — young adults (%) 2015 3 0.2 4
Last year prevalence of drug use — all adults (%) 2015 2 0.1 2.3
All treatment entrants (%) 2014 37 0 37
First-time treatment entrants (%) 2014 35 0 40
Quantity of cocaine seized (kg) 2015 21 620.9 2 21 621
Number of cocaine seizures 2015 38 273  16 38 273
Purity (%) (minimum and maximum values registered) No data No data 0 100
Price per gram (EUR) (minimum and maximum values registered) No data No data 10 248.5
Amphetamines     
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 1.3 0.8 6.5
Last year prevalence of use — young adults (%) 2015 1 0.1 3.1
Last year prevalence of drug use — all adults (%) 2015 0.5 0 1.6
All treatment entrants (%) 2014 1 0 70
First-time treatment entrants (%) 2014 2 0 75
Quantity of amphetamine seized (kg) 2015 323 0 3 796
Number of amphetamine seizures 2015 4 336  1 10 388
Purity — amphetamine (%)  
(minimum and maximum values registered)
No data No data 0 100
Price per gram — amphetamine (EUR) 
 (minimum and maximum values registered)
No data No data 1 139.8
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   EU range
 Year Country data Minimum Maximum
MDMA     
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 1 0.5 5.2
Last year prevalence of use — young adults (%) 2015 1.3 0.1 6.6
Last year prevalence of drug use — all adults (%) 2015 0.6 0.1 3.4
All treatment entrants (%) 2014 0 0 2
First-time treatment entrants (%) 2014 0 0 2
Quantity of MDMA seized (tablets) 2015 135 110 54 5 673 901
Number of MDMA seizures 2015 2 958  3 5 012
Purity (mg of MDMA base per unit)  
(minimum and maximum values registered)
No data No data 0 293
Price per tablet (EUR) (minimum and maximum values registered) No data No data 0.5 60
Opioids     
High-risk opioid use (rate/1 000) 2014 2.1 0.3 8.1
All treatment entrants (%) 2014 25 4 93
First-time treatment entrants (%) 2014 11 2 87
Quantity of heroin seized (kg) 2015 256 0 8 294
Number of heroin seizures 2015 7 755  2 12 271
Purity — heroin (%) (minimum and maximum values registered) No data No data 0 96
Price per gram — heroin (EUR)  
(minimum and maximum values registered)
No data No data 3.1 214
Drug-related infectious diseases/injecting/deaths     
Newly diagnosed HIV cases related to injecting drug use  
(cases/million population, Source: ECDC)
2015 2.1 0 44
HIV prevalence among PWID* (%) 2014 30.9 0 30.9
HCV prevalence among PWID* (%) 2014 66.6 15.7 83.5
Injecting drug use (cases rate/1 000 population) 2014 0.2 0.2 9.2
Drug-induced deaths — all adults (cases/million population) 2014 14.8 1.6 102.7
Health and social responses     
Syringes distributed through specialised programmes 2014 1 483 399  164 12 314 781
Clients in substitution treatment 2014 61 859  252 168 840
Treatment demand     
All clients 2014 48 926  282 124 234
First-time clients 2014 23 656  24 40 390
Drug law offences     
Number of reports of offences 2015 411 157  472 411 157
Offences for use/possession 2015 390 843  359 390 843
* PWID — People who inject drugs.     
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NB: Caution is required in interpreting data when countries are compared using any single measure, as, for example, differences may be due to reporting 
practices. Detailed information on methodology, qualifications on analysis and comments on the limitations of the information available can be found in the 
EMCDDA Statistical Bulletin. Countries with no data available are marked in white.
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About the EMCDDA
About our partner in Spain
The Spanish national focal point is located within the Government 
Delegation for the National Plan on Drugs, a government organisation 
under the auspice of the Ministry of Health, Social Policy and Equality. 
The Government Delegation for the National Plan on Drugs is 
entrusted with coordination of different aspects of drug policy, ranging 
from drug trafficking to responses to the drug problem.
Government Delegation for National 
Plan on Drugs (Delegación del Gobierno 
para el Plan Nacional sobre Drogas)
Plaza de España, 17
E-28008 Madrid
Spain
Tel. +34 91 822 61 25
Fax +34 91 822 60 95
Head of national focal point: Mr Francisco de 
Asís Babín Vich — relinstipnd@msssi.es
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the 
central source and confirmed authority on drug-related issues in Europe. For over 
20 years, it has been collecting, analysing and disseminating scientifically sound 
information on drugs and drug addiction and their consequences, providing its 
audiences with an evidence-based picture of the drug phenomenon at European 
level. 
The EMCDDA’s publications are a prime source of information for a wide range  
of audiences including: policymakers and their advisors; professionals and  
researchers working in the drugs field; and, more broadly, the media and general  
public. Based in Lisbon, the EMCDDA is one of the decentralised agencies of the 
European Union.
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